Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 210

1.

Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype.

Carafa V, Altucci L, Nebbioso A.

Front Pharmacol. 2019 Jan 30;10:38. doi: 10.3389/fphar.2019.00038. eCollection 2019. Review.

2.

Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes.

Yi G, Wierenga ATJ, Petraglia F, Narang P, Janssen-Megens EM, Mandoli A, Merkel A, Berentsen K, Kim B, Matarese F, Singh AA, Habibi E, Prange KHM, Mulder AB, Jansen JH, Clarke L, Heath S, van der Reijden BA, Flicek P, Yaspo ML, Gut I, Bock C, Schuringa JJ, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA.

Cell Rep. 2019 Jan 22;26(4):1059-1069.e6. doi: 10.1016/j.celrep.2018.12.098.

3.

Comment on: LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis.

Franci G, Dell'Aversana C, Stelitano D, Rinaldi M, Altucci L.

Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):1-2. doi: 10.26355/eurrev_201901_16739. No abstract available.

4.

I BET on anti-FGFR to fight cancer resistance.

Benedetti R, Altucci L.

EMBO Mol Med. 2019 Feb;11(2). pii: e10116. doi: 10.15252/emmm.201810116. No abstract available.

5.

Correction: Sonoporation by microbubbles as gene therapy approach against liver cancer.

Rinaldi L, Folliero V, Palomba L, Zannella C, Isticato R, Di Francia R, Berretta M, de Sio I, Adinolfi LE, Morelli G, Lastoria S, Altucci L, Pedone C, Galdiero M, Franci G.

Oncotarget. 2018 Oct 30;9(85):35600. doi: 10.18632/oncotarget.26305. eCollection 2018 Oct 30.

6.

Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents.

Brindisi M, Ulivieri C, Alfano G, Gemma S, de Asís Balaguer F, Khan T, Grillo A, Chemi G, Menchon G, Prota AE, Olieric N, Lucena-Agell D, Barasoain I, Diaz JF, Nebbioso A, Conte M, Lopresti L, Magnano S, Amet R, Kinsella P, Zisterer DM, Ibrahim O, O'Sullivan J, Morbidelli L, Spaccapelo R, Baldari C, Butini S, Novellino E, Campiani G, Altucci L, Steinmetz MO, Brogi S.

Eur J Med Chem. 2019 Jan 15;162:290-320. doi: 10.1016/j.ejmech.2018.11.004. Epub 2018 Nov 3.

PMID:
30448418
7.

Biological interactions of biocompatible and water-dispersed MoS2 nanosheets with bacteria and human cells.

Kaur J, Singh M, Dell'Aversana C, Benedetti R, Giardina P, Rossi M, Valadan M, Vergara A, Cutarelli A, Montone AMI, Altucci L, Corrado F, Nebbioso A, Altucci C.

Sci Rep. 2018 Nov 6;8(1):16386. doi: 10.1038/s41598-018-34679-y.

8.

3-Chloro-N'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.

Sarno F, Papulino C, Franci G, Andersen JH, Cautain B, Melardo C, Altucci L, Nebbioso A.

Front Pharmacol. 2018 Sep 7;9:1006. doi: 10.3389/fphar.2018.01006. eCollection 2018.

9.

Sonoporation by microbubbles as gene therapy approach against liver cancer.

Rinaldi L, Folliero V, Palomba L, Zannella C, Isticato R, Di Francia R, Berretta M, de Sio I, Adinolfi LE, Morelli G, Lastoria S, Altucci L, Pedone C, Galdiero M, Franci G.

Oncotarget. 2018 Aug 14;9(63):32182-32190. doi: 10.18632/oncotarget.25875. eCollection 2018 Aug 14. Erratum in: Oncotarget. 2018 Oct 30;9(85):35600.

10.

Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase.

Franci G, Folliero V, Cammarota M, Zannella C, Sarno F, Schiraldi C, de Lera AR, Altucci L, Galdiero M.

Sci Rep. 2018 Sep 3;8(1):13117. doi: 10.1038/s41598-018-31135-9.

11.

Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.

Brindisi M, Senger J, Cavella C, Grillo A, Chemi G, Gemma S, Cucinella DM, Lamponi S, Sarno F, Iside C, Nebbioso A, Novellino E, Shaik TB, Romier C, Herp D, Jung M, Butini S, Campiani G, Altucci L, Brogi S.

Eur J Med Chem. 2018 Sep 5;157:127-138. doi: 10.1016/j.ejmech.2018.07.069. Epub 2018 Jul 31.

PMID:
30092367
12.

Forskolin Sensitizes Human Acute Myeloid Leukemia Cells to H3K27me2/3 Demethylases GSKJ4 Inhibitor via Protein Kinase A.

Illiano M, Conte M, Sapio L, Nebbioso A, Spina A, Altucci L, Naviglio S.

Front Pharmacol. 2018 Jul 20;9:792. doi: 10.3389/fphar.2018.00792. eCollection 2018.

13.

Synthesis and Biological Evaluation of Tripartin, a Putative KDM4 Natural Product Inhibitor, and 1-Dichloromethylinden-1-ol Analogues.

Guillade L, Sarno F, Tarhonskaya H, Nebbioso A, Alvarez S, Kawamura A, Schofield CJ, Altucci L, de Lera ÁR.

ChemMedChem. 2018 Sep 19;13(18):1949-1956. doi: 10.1002/cmdc.201800377. Epub 2018 Aug 21.

PMID:
30047603
14.

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.

Rosati G, Del Gaudio N, Scarano E, Cifarelli RA, Altucci L, Bilancia D.

Medicine (Baltimore). 2018 Jun;97(25):e11178. doi: 10.1097/MD.0000000000011178.

15.

Cancer epigenetics: Moving forward.

Nebbioso A, Tambaro FP, Dell'Aversana C, Altucci L.

PLoS Genet. 2018 Jun 7;14(6):e1007362. doi: 10.1371/journal.pgen.1007362. eCollection 2018 Jun. Review.

16.

Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia.

Singh AA, Petraglia F, Nebbioso A, Yi G, Conte M, Valente S, Mandoli A, Scisciola L, Lindeboom R, Kerstens H, Janssen-Megens EM, Pourfarzad F, Habibi E, Berentsen K, Kim B, Logie C, Heath S, Wierenga ATJ, Clarke L, Flicek P, Jansen JH, Kuijpers T, Yaspo ML, Valle VD, Bernard O, Gut I, Vellenga E, Stunnenberg HG, Mai A, Altucci L, Martens JHA.

Oncotarget. 2018 May 22;9(39):25647-25660. doi: 10.18632/oncotarget.25429. eCollection 2018 May 22.

17.

Combined HAT/EZH2 modulation leads to cancer-selective cell death.

Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-Megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L.

Oncotarget. 2018 May 22;9(39):25630-25646. doi: 10.18632/oncotarget.25428. eCollection 2018 May 22.

18.

Pro-inflammatory cytokines activate hypoxia-inducible factor 3α via epigenetic changes in mesenchymal stromal/stem cells.

Cuomo F, Coppola A, Botti C, Maione C, Forte A, Scisciola L, Liguori G, Caiafa I, Ursini MV, Galderisi U, Cipollaro M, Altucci L, Cobellis G.

Sci Rep. 2018 Apr 11;8(1):5842. doi: 10.1038/s41598-018-24221-5.

19.

RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer.

Carafa V, Nebbioso A, Cuomo F, Rotili D, Cobellis G, Bontempo P, Baldi A, Spugnini EP, Citro G, Chambery A, Russo R, Ruvo M, Ciana P, Maravigna L, Shaik J, Radaelli E, De Antonellis P, Tarantino D, Pirolli A, Ragno R, Zollo M, Stunnenberg HG, Mai A, Altucci L.

Clin Cancer Res. 2018 Jun 15;24(12):2886-2900. doi: 10.1158/1078-0432.CCR-17-3081. Epub 2018 Mar 13.

PMID:
29535128
20.

HDAC inhibitors as epigenetic regulators for cancer immunotherapy.

Conte M, De Palma R, Altucci L.

Int J Biochem Cell Biol. 2018 May;98:65-74. doi: 10.1016/j.biocel.2018.03.004. Epub 2018 Mar 10. Review.

PMID:
29535070

Supplemental Content

Loading ...
Support Center